WHEB Commentary

Seb Beloe

How WHEB’s investments are helping to cut the costs of healthcare


Healthcare has been a hot topic for US politicians for much of the past five years, and is likely to remain so for some time yet.

Notwithstanding the capriciousness of political views on the topic, the ongoing ageing of populations around the world continues to provide solid and well-understood foundations for the long-term growth in the sector. Beyond this, the shape and focus of healthcare continues to evolve, with the proportion of the global disease burden caused by chronic conditions growing from 46% in 2001 to nearly 60% in 2020[1].

As people live longer, but also with more chronic health conditions, so healthcare costs have mushroomed around the world. The US is of course the stand-out example of this where healthcare costs now constitute over 17% of GDP[2]. However the same pattern is evident in virtually all countries, with most developed world economies spending >10% of GDP on healthcare, and developing economies spending 5-6% on healthcare[3].

Pressure to cut costs in healthcare while maintaining positive health outcomes has become a key preoccupation for government funded health schemes, as well as for insurance companies and other commercial payers. Technological developments as well as changes in the market are providing a myriad of opportunities for businesses that demonstrate real cost savings for end payers.

Within WHEB’s investment strategy, ‘Health’ is a key investment theme. We believe that companies that are cutting the cost of healthcare are playing a central role in enabling higher quality healthcare to be accessed by a growing proportion of the world’s population. The WHEB strategy is currently invested in six companies representing approximately 7% of the fund that are primarily focused on cutting costs in healthcare.

For example, in the US, the fund is invested in a number of businesses that use their scale to negotiate reduced costs on behalf of their clients. This includes both Premier Inc. and CVS Health Corporation who are major purchasers of healthcare equipment/consumables and of pharmaceuticals respectively. CVS Health, as an operator of a US pharmacy network, has also been aggressively promoting generic over branded pharmaceuticals as an additional strategy for cutting costs for their customers.

New technology is also playing a central role in cutting healthcare costs. The fund is invested in one UK-based business BTG plc, which is developing novel therapies focused on the minimally invasive diagnosis and treatment of cancer, varicose veins, blood clots and a variety of other conditions.

Better management and interrogation of big data in healthcare is also yielding significant potential for cost reductions. The fund is, for example, invested in Cerner, a major provider of healthcare information technology (IT) solutions that help manage healthcare records better, and identify better treatment options. HMS Holdings also uses healthcare IT to identify payment inaccuracies, helping save money for public healthcare schemes such as the US Government schemes Medicaid and Medicare.

The most recent investment in the fund is in a business called Centene which is a US health insurer. Centene provides healthcare insurance for low income and vulnerable groups in the US. Their whole focus is on providing low cost access to healthcare to these populations in the US utilising their scale and technology to drive down the cost of healthcare for these groups.

Views on government’s role in healthcare provision will likely remain hotly contested in the US and elsewhere for some time to come. Removing costs and improving efficiencies will, in our view however, remain a key part of the solution whichever political view holds s

[1] The World Health Organisation (WHO)

[2] Organisation for Economic Cooperation and Development (OECD)

[3] WHO and the World Bank

Recent posts

  • The UK through a sustainability lens – November monthly
  • Market jitters and long term solutions to sustainability challenges – October Monthly
  • Why we invest in – Aptiv; driving change in the automotive industry
  • WHEB is proud to be accredited as a Living Wage Employer
  • Crosswinds and fundamentals – September Monthly
  • Engagement without the punch-ups
  • Why we invest in – Orpea
  • Tesla; our view – August Monthly
  • Another chance to hear the presentations from WHEB’s 2018 Annual Investor Conference
  • How can we make impact investing more accessible?
  • Archive

  • December 2018 (1)
  • November 2018 (2)
  • October 2018 (4)
  • September 2018 (2)
  • August 2018 (4)
  • July 2018 (1)
  • June 2018 (1)
  • May 2018 (1)
  • April 2018 (2)
  • March 2018 (2)
  • February 2018 (1)
  • January 2018 (1)
  • December 2017 (3)
  • November 2017 (1)
  • July 2017 (3)
  • June 2017 (1)
  • May 2017 (1)
  • April 2017 (1)
  • February 2017 (2)
  • November 2016 (1)
  • August 2016 (1)
  • July 2016 (1)
  • June 2016 (1)
  • May 2016 (1)
  • April 2016 (2)
  • February 2016 (1)
  • December 2015 (1)
  • November 2015 (3)
  • October 2015 (1)
  • September 2015 (1)
  • July 2015 (2)
  • April 2015 (2)
  • February 2015 (2)
  • December 2014 (2)
  • November 2014 (3)
  • October 2014 (4)
  • August 2014 (1)
  • July 2014 (3)
  • June 2014 (1)
  • April 2014 (2)
  • March 2014 (2)
  • February 2014 (3)
  • January 2014 (4)
  • December 2013 (4)
  • October 2013 (5)
  • September 2013 (3)
  • July 2013 (4)
  • June 2013 (2)
  • May 2013 (4)
  • April 2013 (2)
  • March 2013 (4)
  • February 2013 (6)
  • January 2013 (2)
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (4)
  • September 2012 (2)
  • August 2012 (1)
  • July 2012 (3)
  • June 2012 (3)
  • May 2012 (6)
  • April 2012 (4)
  • March 2012 (5)